1
|
Ishizaki T, Takeuchi Y, Ishibashi K, Gotoh N, Hirata E, Kuroda K. Cryopreservation of tissues by slow-freezing using an emerging zwitterionic cryoprotectant. Sci Rep 2023; 13:37. [PMID: 36593263 PMCID: PMC9807565 DOI: 10.1038/s41598-022-23913-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 11/07/2022] [Indexed: 01/04/2023] Open
Abstract
Cryopreservation of tissues is a tough challenge. Cryopreservation is categorized into slow-freezing and vitrification, and vitrification has recently been recognized as a suitable method for tissue cryopreservation. On the contrary, some researchers have reported that slow-freezing also has potential for tissue cryopreservation. Although conventional cryoprotectants have been studied well, some novel ones may efficiently cryopreserve tissues via slow-freezing. In this study, we used aqueous solutions of an emerging cryoprotectant, an artificial zwitterion supplemented with a conventional cryoprotectant, dimethyl sulfoxide (DMSO), for cell spheroids. The zwitterion/DMSO aqueous solutions produced a better cryoprotective effect on cell spheroids, which are the smallest units of tissues, compared to that of a commercial cryoprotectant. Cryopreservation with the zwitterion/DMSO solutions not only exhibited better cell recovery but also maintained the functions of the spheroids effectively. The optimized composition of the solution was 10 wt% zwitterion, 15 wt% DMSO, and 75 wt% water. The zwitterion/DMSO solution gave a higher number of living cells for the cryopreservation of mouse tumor tissues than a commercial cryoprotectant. The zwitterion/DMSO solution was also able to cryopreserve human tumor tissue, a patient-derived xenograft.
Collapse
Affiliation(s)
- Takeru Ishizaki
- Faculty of Biological Science and Technology, Institute of Science and Engineering, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan
| | - Yasuto Takeuchi
- Cancer Research Institute, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan
| | - Kojiro Ishibashi
- Cancer Research Institute, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan
| | - Noriko Gotoh
- Cancer Research Institute, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan
| | - Eishu Hirata
- Cancer Research Institute, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan. .,WPI-Nano Life Science Institute, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan.
| | - Kosuke Kuroda
- Faculty of Biological Science and Technology, Institute of Science and Engineering, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan. .,NanoMaterials Research Institute, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Japan.
| |
Collapse
|
2
|
Rae C, Amato F, Braconi C. Patient-Derived Organoids as a Model for Cancer Drug Discovery. Int J Mol Sci 2021; 22:ijms22073483. [PMID: 33801782 PMCID: PMC8038043 DOI: 10.3390/ijms22073483] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Revised: 03/23/2021] [Accepted: 03/24/2021] [Indexed: 12/12/2022] Open
Abstract
In the search for the ideal model of tumours, the use of three-dimensional in vitro models is advancing rapidly. These are intended to mimic the in vivo properties of the tumours which affect cancer development, progression and drug sensitivity, and take into account cell–cell interactions, adhesion and invasiveness. Importantly, it is hoped that successful recapitulation of the structure and function of the tissue will predict patient response, permitting the development of personalized therapy in a timely manner applicable to the clinic. Furthermore, the use of co-culture systems will allow the role of the tumour microenvironment and tissue–tissue interactions to be taken into account and should lead to more accurate predictions of tumour development and responses to drugs. In this review, the relative merits and limitations of patient-derived organoids will be discussed compared to other in vitro and ex vivo cancer models. We will focus on their use as models for drug testing and personalized therapy and how these may be improved. Developments in technology will also be considered, including the use of microfluidics, 3D bioprinting, cryopreservation and circulating tumour cell-derived organoids. These have the potential to enhance the consistency, accessibility and availability of these models.
Collapse
Affiliation(s)
- Colin Rae
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; (C.R.); (F.A.)
| | - Francesco Amato
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; (C.R.); (F.A.)
| | - Chiara Braconi
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; (C.R.); (F.A.)
- Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK
- Correspondence:
| |
Collapse
|